| Literature DB >> 32124729 |
Hisham Ahmed Imad1, Weerapong Phumratanaprapin1, Benjaluck Phonrat1, Kesinee Chotivanich1, Prakaykaew Charunwatthana1, Sant Muangnoicharoen1, Srisin Khusmith2, Terapong Tantawichien3, Juthamas Phadungsombat4, Emi Nakayama5,4, Eiji Konishi6, Tatsuo Shioda5,4.
Abstract
Dengue is the most common mosquito-borne flaviviral infection in the world today. Several factors contribute and act synergistically to cause severe infection. One of these is dysregulated host immunological mediators that cause transient pathophysiology during infection. These mediators act on the endothelium to increase vascular permeability, which leads to plasma leakage compromising hemodynamics and coagulopathy. We conducted a prospective study to explore the expression of pro- and anti-inflammatory cytokines and how they relate to clinical dengue manifestations, by assessing their dynamics through acute dengue infection in adults admitted to the Hospital for Tropical Diseases, Bangkok, Thailand. We performed cytokine analysis at three phases of infection for 96 hospitalized adults together with serotyping of confirmed dengue infection during the outbreaks of 2015 and 2016. The serum concentrations of seven cytokines (interleukin [IL]-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor alpha, and interferon gamma) were measured in duplicate using a commercial kit (Bio-Plex Human Cytokine Assay). In this study, the cytokine profile was suggestive of a T-helper 2 response. Most patients had secondary infection, and the levels of viremia were higher in patients with plasma leakage than those without plasma leakage. In addition, we observed that bleeding and hepatitis were associated with significantly higher levels of IL-8 during the early phases of infection. Furthermore, IL-6 levels in the early phase of infection were also elevated in bleeding patients with plasma leakage. These results suggest that IL-6 and IL-8 may act in synergy to cause bleeding in patients with plasma leakage.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32124729 PMCID: PMC7204576 DOI: 10.4269/ajtmh.19-0487
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Demographic data, clinical findings, and laboratory parameters in dengue infection
| Parameters | Dengue fever = 59, | Dengue hemorrhagic fever = 37, | |
|---|---|---|---|
| Females | 20 (33.89) | 18 (48.64) | 0.2 |
| Males | 39 (66.10) | 19 (51.35) | |
| Age (years), mean ± SD | 31 ± 11 | 33 ± 11 | 0.44 |
| Primary infection, age mean ± SD | 25 ± 11 | 0 | NA |
| Secondary infection, age mean ± SD | 32 ± 11 | 33 ± 11 | 0.11 |
| Duration of illness, mean ± SD | 6.95 ± 0.9 | 7.8 ± 0.8 | |
| Fever | 59 (100) | 37 (100) | NA |
| Headache | 53 (89.83) | 37 (100) | |
| Myalgia/arthralgia | 43 (72.88) | 34 (91.89) | |
| Nausea/vomiting | 29 (49.15) | 20 (54.05) | 0.75 |
| Lymphadenopathy | 21 (35.59) | 22 (59.45) | |
| Hepatomegaly | 18 (30.50) | 15 (40.50) | 0.31 |
| Bleeding | 20 (32.78) | 20 (54.05) |
NA = not applicable. The data in the table represent the demographic data and clinical findings in DF and DHF. The clinical findings are represented as the actual number and percentage. The laboratory parameters are represented as the median ± SD. The chi-square test was used to determine the differences in clinical findings in both groups. The Mann–Whitney U-test was used to determine the P-value between two groups using the median value. Bold indicates statistically significant P-values.
Figure 1.Cytokine expression during the three phases of dengue infection.
Figure 2.Cytokine profile during the three phases of infection dengue fever vs. dengue hemorrhagic fever.
Figure 3.Viral load during the acute phase in dengue fever and dengue hemorrhagic fever.
Figure 4.Cytokine profile for bleeding during the three phases of infection.
Figure 5.Cytokine profile for bleeding in dengue hemorrhagic fever during the three phases of infection.
Figure 6.Cytokine profile for bleeding in dengue fever during the three phases of infection.
Figure 7.Cytokine profile during the three phases of infection for severe hepatitis (AST/ALT ≥ 400 U/L).